ClinicalTrials.gg
CompletedNCT03668613Updated May 16, 2025Results posted

Study to Assess the Long-term Safety, Tolerability, Efficacy of Secukinumab in Pediatric Patients of Age 6 to <18 Years, With Moderate to Severe Plaque Psoriasis

A Phase 3 interventional study of secukinumab low dose and secukinumab high dose in Moderate to Severe Chronic Plaque-type Psoriasis, sponsored by Novartis Pharmaceuticals. Completed at 23 sites in 9 countries. Open to participants aged 6 Years to 17 Years. Per ClinicalTrials.gov, last updated 2025-05-16.

Sponsored by Novartis Pharmaceuticals (part of Novartis) · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
84
Allocation
Randomized
Ages
6 Years to 17 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 10 studies testing secukinumab in Skin Diseases — none open to participants now, none under way, none of them phase 3. secukinumab · Skin Diseases.

Enrollment
8th of 10
84 · median 156
Started
2018
the only one that year
Phase 3
7 of 10
none open now
Registered
9th of 10
by date
Lead sponsor
9 of 10
Novartis Pharmaceuticals

Among the 10 studies testing secukinumab in Skin Diseases, this one is the 8th largest by enrollment, is the only one that started in 2018, is one of 7 in phase 3, and was the 9th registered.

Skin Diseases

497 studies on the registry are indexed under Skin Diseases; 78 are open to participants now.

Browse Skin Diseases studies →

Open to participants now

None of the 10 studies testing secukinumab in Skin Diseases is open now. The open studies under Skin Diseases, anywhere →

About secukinumab

secukinumab: first FDA approval 2015 (COSENTYX), first EMA approval 2015. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 55 Skin Diseases studies recruiting now, 27 (49%) set no upper age limit and 18 (33%) stop at 75 or younger; 20 take children under 18; 20 take healthy volunteers.

This study: 6 Years to 17 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 10 studies testing secukinumab in Skin Diseases as a file.
02

Study summary

This was an open-label, parallel-group, two-arm, multicenter study in pediatric subjects aged 6 years to less than 18 years, at randomization, with moderate to severe chronic plaque psoriasis. 84 subjects (most with moderate severity) were enrolled. Subjects were stratified by weight and disease severity.

Read the detailed description

This was an open-label, parallel group, two-arm, multi-center, trial in pediatric subjects aged 6 years to less than 18 years, at randomization, with moderate to severe chronic, plaque psoriasis. The study consists of 3 periods: screening (up to 4 weeks), treatment (Week 208) and post-treatment follow-up (Week 224).

Approximately 80 subjects (at least 60 subjects with moderate psoriasis) were planned to be enrolled in about 40 centers worldwide and targeted to have at least 5 subjects in the \< 25kg body weight, and at least 10 subjects in each of the other two weight groups (25-\< 50 kg and ≥ 50 kg). Adolescents (12-\< 18 years) and children (6-\< 12 years) were included from the beginning of this study, since the DMC had approved already the enrollment of children (6-\< 12 years) in the study CAIN457A2310 (NCT02471144). Subjects received the appropriate dose based on their body weight category.

For the statistical analysis for outcome measures 1 and 2, there was no 'within study' control arm. A historical placebo control was obtained using data from qualifying trials and used as the comparator for the primary and key secondary endpoint analysis. This was in line with the guidance from and discussions with Health Authorities including FDA and EMA (PDCO), which suggested reducing placebo exposure as well as overall clinical trial burden for the pediatric population and accepted an extrapolation approach (EMA 2012). Historical placebo data included in this study were based on clinical appropriateness and alignment of definitions (endpoints, clinical disease population and time point of assessment). Integrated in the analysis were placebo data from Novartis-reported secukinumab adult placebo-controlled studies (CAIN457A2302 (NCT01544595 and NCT01365455), CAIN457A2303 (NCT01544595 and NCT01358578), CAIN457A2308 (NCT01555125) and CAIN457A2309 (NCT01636687)) and pediatric placebo-controlled study CAIN457A2310. In addition, pediatric placebo-controlled study data from the literature on other biologics (e.g. etanercept, ustekinumab) were utilized (Paller et al 2008, Landells et al 2015).

If the subject moved into a higher or lower weight group at two consecutive visits with weight measurements during the maintenance (from Week 12 onwards as assessed at 4 weekly visits or during extension treatment period (as assessed at scheduled site visits), then the subject was dosed according to the new (higher or lower) weight group respectively.

03

Conditions studied

  • Moderate to Severe Chronic Plaque-type Psoriasis

Keywords

  • pediatric
  • secukinumab
  • plaque psoriasis
  • AIN457A
  • Skin condition
  • skin disease
  • itching condition
  • psoriasis vulgaris
  • relapsing/remitting psoriasis
  • immune-mediated systemic disease
  • skin lesions
  • red skin lesions
  • scaly patches
  • papules
  • plaques
  • itching
04

Who can participate

Ages eligible
6 Years to 17 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Written informed assent and parental permission (age as per local law) obtained at screening before any assessment is performed.
  2. Must be 6 to less than 18 years of age at the time of randomization
  3. Moderate to Severe plaque psoriasis, defined as a PASI score ≥ 12, and IGA mod 2011 score of ≥ 3, and BSA involvement of ≥10%, at randomization.
  4. Subject being regarded by the investigator to be a candidate for systemic therapy.

Exclusion criteria

Exclusion Criteria:

  1. Forms of psoriasis other than chronic plaque-type active at randomization
  2. Drug-induced psoriasis
  3. Ongoing use of prohibited treatments
  4. Female subjects of defined as all women physiologically capable of becoming pregnant, unless they are using effective methods of during dosing and for 16 weeks after stopping study treatment
  5. Pregnant or nursing (lactating) females
  6. Subjects with total WBC count \<2,500/μL, or \<100,000/μL or neutrophils \<1,500/μL or \<8.5 g/dL at screening
  7. Previous exposure to secukinumab or any other biologic drug directly targeting IL-17 or the IL-17 receptor
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
84 participants (actual)

Study arms

  • Experimental
    secukinumab low dose

    secukinumab low dose

    Drug: secukinumab low dose

  • Experimental
    secukinumab high dose

    secukinumab high dose

    Drug: secukinumab high dose

Interventions

06

What researchers measure

Primary outcomes

  1. Number and Percentage of Participants With PASI 75 Response

    Psoriasis Area and Severity Index (PASI):Combined assessment of lesion severity and affected area into a single score: 0 (no disease) to 72(maximal disease). Body is divided into 4 areas for scoring (head, trunk, upper limbs and lower limbs); each area is scored by itself and scores are combined for final PASI. For each area, percent of skin involved is estimated: 0 (0%) to 6 (90-100%), and severity is estimated by clinical signs, Erythema,Thickening (plaque elevation, induration) \& Scaling(desquamation). Scale 0 (none) to 4 (maximum). Final PASI = sum of severity parameters for each area\* area score weight of section(head: 0.1, upper limbs: 0.2 body: 0.3 lower limbs: 0.4). Psoriasis Area and Severity Index (PASI) will be assessed/calculated as per standard procedure. PASI 75 represents the percentage (or number)of patients who have achieved a 75% or more reduction in their PASI score from baseline. PASI 100 indicates patients who have achieved a complete resolution of all disease.

    Time frame: Week 12

  2. Number and Percentage of Participants With IGA Mod 2011 0 or 1 Response

    Investigator will assess the disease using the validated Investigator Global Assessment (IGA) mod 2011 and rate the disease from a score of 0 (clear skin) to 4 (severe disease)

    Time frame: Week 12

Secondary outcomes

  1. Number and Percentage of Participants With PASI 90 Response

    Psoriasis Area and Severity Index (PASI) was assessed/calculated as per the standard procedure. PASI 90 represents the percentage (or number) of patients who have achieved a 90% or more reduction in their PASI score from baseline. PASI 100 indicates patients who have achieved a complete resolution of all disease.

    Time frame: Week 12

  2. Secukinumab Concentration in Serum

    Mean (Standard Deviation) Secukinumab concentration levels in serum over time.

    Time frame: Baleine, Weeks 4, 12, 13, 14, 15, 16, 24, 52, 104, 156, 208

  3. Summary Table of Adverse Events

    An adverse event (AE) is any untoward medical occurrence (e.g. any unfavorable and unintended sign \[including abnormal laboratory findings\], symptom or disease) in a clinical investigation participant after providing written informed consent for participation in the study. Treatment emergent adverse events in this study are events that started after the first dose of study treatment and until 84 days after the last study treatment, or events present prior to the first dose of treatment which increased in severity based on preferred term within 84 days after the last study treatment.

    Time frame: Adverse events are reported from the first dose of study-drug until the end of the treatment period (at Week 208) plus 16 weeks additional follow up reporting, for a maximum timeframe of approximately 224 weeks.

07

Results

Posted Jul 23, 2021

Participant flow

A total of 92 subjects were screened of which 84 subjects completed the screening phase and were randomized to the Secukinumab Low dose and High dose groups in a 1:1 ratio.

Participant flow — Overall Study
MilestoneAIN457 Low DoseAIN457 High Dose
Started4242
Completed3136
Not completed116
Withdrew: Adverse event12
Withdrew: Lack of efficacy51
Withdrew: Pregnancy02
Withdrew: Protocol violation10
Withdrew: Physician decision10
Withdrew: Withdrawal by subject21
Withdrew: Guardian decision10

Outcome measures

PrimaryNumber and Percentage of Participants With PASI 75 Response

Psoriasis Area and Severity Index (PASI):Combined assessment of lesion severity and affected area into a single score: 0 (no disease) to 72(maximal disease). Body is divided into 4 areas for scoring (head, trunk, upper limbs and lower limbs); each area is scored by itself and scores are combined for final PASI. For each area, percent of skin involved is estimated: 0 (0%) to 6 (90-100%), and severity is estimated by clinical signs, Erythema,Thickening (plaque elevation, induration) \& Scaling(desquamation). Scale 0 (none) to 4 (maximum). Final PASI = sum of severity parameters for each area\* area score weight of section(head: 0.1, upper limbs: 0.2 body: 0.3 lower limbs: 0.4). Psoriasis Area and Severity Index (PASI) will be assessed/calculated as per standard procedure. PASI 75 represents the percentage (or number)of patients who have achieved a 75% or more reduction in their PASI score from baseline. PASI 100 indicates patients who have achieved a complete resolution of all disease.

Time frame:
Week 12
Reported as:
Count of participants · Participants
Number and Percentage of Participants With PASI 75 Response
ParticipantsAIN457 Low DoseAIN457 High Dose
Number and Percentage of Participants With PASI 75 Response3939
Statistical analysis
  • AIN457 Low Dose · Bayesian method using (MAP) · Predicted log-or: 4.862 · 95% CI 3.422 to 6.782
  • AIN457 High Dose · Bayesian method using (MAP) · Predicted log-or: 4.836 · 95% CI 3.422 to 6.772
PrimaryNumber and Percentage of Participants With IGA Mod 2011 0 or 1 Response

Investigator will assess the disease using the validated Investigator Global Assessment (IGA) mod 2011 and rate the disease from a score of 0 (clear skin) to 4 (severe disease)

Time frame:
Week 12
Reported as:
Count of participants · Participants
Number and Percentage of Participants With IGA Mod 2011 0 or 1 Response
ParticipantsAIN457 Low DoseAIN457 High Dose
Number and Percentage of Participants With IGA Mod 2011 0 or 1 Response3335
Statistical analysis
  • AIN457 Low Dose · Bayesian method using (MAP) · Predicted log -or: 4.292 · 95% CI 2.638 to 6.513
  • AIN457 High Dose · Bayesian method using (MAP) · Predicted log-or: 4.606 · 95% CI 2.919 to 6.780
SecondaryNumber and Percentage of Participants With PASI 90 Response

Psoriasis Area and Severity Index (PASI) was assessed/calculated as per the standard procedure. PASI 90 represents the percentage (or number) of patients who have achieved a 90% or more reduction in their PASI score from baseline. PASI 100 indicates patients who have achieved a complete resolution of all disease.

Time frame:
Week 12
Reported as:
Count of participants · Participants
Number and Percentage of Participants With PASI 90 Response
ParticipantsAIN457 Low DoseAIN457 High Dose
Number and Percentage of Participants With PASI 90 Response2932
Statistical analysis
  • AIN457 Low Dose · Bayesian method using (MAP) · Predicted log-or: 4.367 · 95% CI 2.916 to 6.202
  • AIN457 High Dose · Bayesian method using (MAP) · Predicted log-or: 4.709 · 95% CI 3.201 to 6.580
SecondarySecukinumab Concentration in Serum

Mean (Standard Deviation) Secukinumab concentration levels in serum over time.

Time frame:
Baleine, Weeks 4, 12, 13, 14, 15, 16, 24, 52, 104, 156, 208
Reported as:
Mean · mcg/mL
Secukinumab Concentration in Serum
mcg/mLAIN457 Low DoseAIN457 High Dose
Baseline0.00 ± 0.000.00 ± 0.00
Week 4 (n=40,40)74.2 ± 33.0135 ± 45.3
Week 12 (n=40, 39)34.8 ± 10.969.6 ± 29.2
Week 13 (n=38,33)47.1 ± 17.491.2 ± 34.1
Week 14 (n=40, 39)40.9 ± 15.578.4 ± 29.8
Week 15 (n=38,35)34.6 ± 12.465.7 ± 28.9
Week 16 (n=40,37)30.9 ± 11.255.2 ± 24.9
Week 24 (n=42, 38)26.0 ± 10.848.0 ± 21.4
Week 52 (n=37,38)25.0 ± 9.0142.7 ± 17.0
Week 104 (n=39,33)21.9 ± 10.839.3 ± 12.1
Week 156 (n=34,32)19.3 ± 8.6835.0 ± 14.1
Week 208 (n=25,28)16.7 ± 6.2538.8 ± 17.2
SecondarySummary Table of Adverse Events

An adverse event (AE) is any untoward medical occurrence (e.g. any unfavorable and unintended sign \[including abnormal laboratory findings\], symptom or disease) in a clinical investigation participant after providing written informed consent for participation in the study. Treatment emergent adverse events in this study are events that started after the first dose of study treatment and until 84 days after the last study treatment, or events present prior to the first dose of treatment which increased in severity based on preferred term within 84 days after the last study treatment.

Time frame:
Adverse events are reported from the first dose of study-drug until the end of the treatment period (at Week 208) plus 16 weeks additional follow up reporting, for a maximum timeframe of approximately 224 weeks.
Reported as:
Count of participants · Participants
Summary Table of Adverse Events
ParticipantsAIN457 Low DoseAIN457 High Dose
Subjects with any AE(s)3335
Subjects with serious or other significant events - Death00
Subjects with serious or other significant events - Non-fatal SAE(s)42
Subjects with serious or other significant events - Discontinued study treatment due to any AE(s)12

Adverse events

Collected over Adverse events are reported from the first dose of study-drug until the end of the treatment period (at Week 208) plus 16 weeks additional follow up reporting, for a maximum timeframe of approximately 224 weeks.. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
AIN457 Low Dose0/42 (0%)4/42 (9.5%)30/42 (71.4%)
AIN457 High Dose0/42 (0%)2/42 (4.8%)27/42 (64.3%)
Most frequent serious events
Most frequent serious events
EventAIN457 Low DoseAIN457 High Dose
Crohn's diseaseGastrointestinal disorders1/420/42
AppendicitisInfections and infestations0/421/42
COVID-19Infections and infestations1/420/42
Infectious mononucleosisInfections and infestations1/420/42
TonsillitisInfections and infestations0/421/42
Tibia fractureInjury, poisoning and procedural complications1/420/42
Intentional self-injuryPsychiatric disorders1/420/42
Most frequent other events
Showing 10 of 17
Most frequent other events
EventAIN457 Low DoseAIN457 High Dose
NasopharyngitisInfections and infestations13/427/42
COVID-19Infections and infestations11/429/42
Viral upper respiratory tract infectionInfections and infestations1/427/42
AcneSkin and subcutaneous tissue disorders7/422/42
PyrexiaGeneral disorders6/421/42
Upper respiratory tract infectionInfections and infestations0/426/42
Abdominal painGastrointestinal disorders4/422/42
TonsillitisInfections and infestations2/424/42
EczemaSkin and subcutaneous tissue disorders4/420/42
LeukopeniaBlood and lymphatic system disorders3/421/42

Baseline characteristics

Age, Customized
Age, Customized(Participants)AIN457 Low DoseAIN457 High DoseTotal
6 to <12 years171633
12 to <18 years252651
Sex: Female, Male
Sex: Female, Male(Participants)AIN457 Low DoseAIN457 High DoseTotal
Female202545
Male221739
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)AIN457 Low DoseAIN457 High DoseTotal
White393877
Black or African American101
Asian101
American Indian or Alaska Native145
08

Study locations

23 sites
  • First OC Dermatology
    Fountain Valley, California 92708, United States
  • Private Practice
    Jacksonville, Florida 32256, United States
  • Novartis Investigative Site
    Lebanon, New Hampshire 03756, United States
  • Texas Derm and Laser Specialists .
    San Antonio, Texas 78218, United States
  • Novartis Investigative Site
    Bruxelles, 1200, Belgium
  • Novartis Investigative Site
    Liege, 4000, Belgium
  • Novartis Investigative Site
    Hradec Kralove, CZE 500 05, Czechia
  • Novartis Investigative Site
    Prague, Prague 1 11000, Czechia
  • Novartis Investigative Site
    Tartu, 50406, Estonia
  • Novartis Investigative Site
    Dresden, 01307, Germany
  • Novartis Investigative Site
    Muenster, 48149, Germany
  • Novartis Investigative Site
    Lima, 1, Peru
  • Novartis Investigative Site
    Warszawa, Mazowian 02 495, Poland
  • Novartis Investigative Site
    Rzeszow, 35 055, Poland
  • Novartis Investigative Site
    Wroclaw, 50-566, Poland
  • Novartis Investigative Site
    Kazan, 420012, Russian Federation
  • Novartis Investigative Site
    Krasnodar, 350020, Russian Federation
  • Novartis Investigative Site
    Moscow, 119296, Russian Federation
  • Novartis Investigative Site
    Saint Petersburg, 191123, Russian Federation
  • Novartis Investigative Site
    Esplugues De Llobregat, Barcelona 08950, Spain
  • Novartis Investigative Site
    Sabadell, Barcelona 08208, Spain
  • Novartis Investigative Site
    Madrid, 28041, Spain
  • Novartis Investigative Site
    Valencia, 46026, Spain
09

References and documents

Publications

  • Magnolo N, Kingo K, Laquer V, Browning J, Reich A, Szepietowski JC, Keefe D, Papanastasiou P, Bao W, Forrer P, Patekar M. Efficacy of Secukinumab Across Subgroups and Overall Safety in Pediatric Patients with Moderate to Severe Plaque Psoriasis: Week 52 Results from a Phase III Randomized Study. Paediatr Drugs. 2022 Jul;24(4):377-387. doi: 10.1007/s40272-022-00507-0. Epub 2022 Jun 13. PubMed 35698000 ↗
  • Magnolo N, Kingo K, Laquer V, Browning J, Reich A, Szepietowski JC, Keefe D, Mazur R, Ghelani P, Forrer P, Wraith L, Patekar M. A phase 3 open-label, randomized multicenter study to evaluate efficacy and safety of secukinumab in pediatric patients with moderate to severe plaque psoriasis: 24-week results. J Am Acad Dermatol. 2022 Jan;86(1):122-130. doi: 10.1016/j.jaad.2021.08.066. Epub 2021 Sep 30. PubMed 34555481 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — Novartis is committed to sharing with qualified external researchers, access to patient-level data and supporting clinical documents from eligible studies. These requests are reviewed and approved by an independent review panel on the basis of scientific merit. All data provided is anonymized to respect the privacy of patients who have participated in the trial in line with applicable laws and regulations. This trial data availability is according to the criteria and process described on www.clinicalstudydatarequest.com.

Data sharing details ↗ · clinicalstudydatarequest.com

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Aug 2018 to primary completion in Sep 2019, 12 months.

Results were first posted in Jul 2021, 1 year 10 months after primary completion. A results delay was requested in Jul 2020.

Of 58 industry-sponsored phase 3 interventional studies under Skin Diseases, half reached primary completion within 19 months of starting (the median), counting those still running; a quarter within 15 and three quarters within 26. This study's 12 months is below that.

Counting every sponsor, half of 60 studies reached it within 19 months; a quarter within 13 and three quarters within 26.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 23, 2018
First posted
Sep 12, 2018
StartActual
Aug 29, 2018
Primary completionActual
Sep 19, 2019
CompletionActual
Sep 12, 2023
Results delay requested
Jul 22, 2020
Results first posted
Jul 23, 2021
Last update
May 16, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 16, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT03668613
Responsible party
Sponsor
First posted
Sep 12, 2018
Start date
Aug 29, 2018
Primary completion
Sep 19, 2019
Completion
Sep 12, 2023
Results posted
Jul 23, 2021
Last update
May 16, 2025

Study contacts

Novartis Pharmaceuticals
study director · Novartis Pharmaceuticals

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in May 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Secukinumab

Start the discussion